Platelet transfusion and survival in adults with acute leukemia

Blumberg, Neil; Heal, Joanna M.; Liesveld, Jane L.; Phillips, Gordon L.; Rowe, J. M.

doi:10.1038/sj.leu.2404920

Cited by 40 publications

(38 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…on April 8, 2019. by guest www.bloodjournal.org From may confer other clinical advantages in terms of patient survival, [16][17][18] platelet refractoriness, 19,20 or transfusion reactions. 19 Shehata et al found that the data describing these effects were inconclusive, suggesting that these observations must be confirmed in adequately powered randomized controlled trials.…”

Section: Discussionmentioning

confidence: 99%

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia

Triulzi

Assmann

Strauss

et al. 2012

Blood

123

192

View full text Add to dashboard Cite

Platelet characteristics, such as platelet dose, platelet source (apheresis vs pooled), platelet donor-recipient ABO compatibility, and duration of platelet storage, can affect posttransfusion platelet increments, but it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding. We performed secondary analyses of platelet transfusions given in the prospective randomized Platelet Dose Study, which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylactic platelet transfusions. The primary outcome of these analyses was time from first transfusion to first World Health Organization > grade 2 bleeding. Platelet transfusion increments were assessed at 0.25 to 4 hours and 16 to 32 hours after platelet transfusion. There were 778 patients evaluable for analysis of time to bleeding. Adjusted models showed that randomized dose strategy, platelet source, ABO compatibility, and duration of storage did not predict this outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia

Triulzi

Assmann

Strauss

et al. 2012

Blood

123

192

View full text Add to dashboard Cite

show abstract

“…In one such study of lymphoma patients, ABO identical PLT transfusions, in combination with leukoreduction of all blood products, was associated with a reduced mean number of days with fever (≥38.5 °C), fewer days of antibiotic administration, fewer units of PLTs and RBCs transfused, and faster neutrophil recovery compared to recipients of ABO mismatched PLTs [50]. In contrast, other studies have demonstrated that there was no difference in the number of PLTs and RBCs transfused to patients who received ABO-major mismatched PLTs compared to those who received ABO identical PLT units [51] as well as no difference in hospital length of stay, fever, or antibiotic use [52]. The TRAP study found no difference in the time to the next PLT transfusion between recipients of ABO identical PLT units and recipients of ABO-major mismatched PLTs [40].…”

Section: Part 1: Plt Transfusion and Abo Compatibilitymentioning

confidence: 99%

Platelet Transfusion - the Art and Science of Compromise

Cid

Harm

Yazer

2013

Transfus Med Hemother

View full text Add to dashboard Cite

Many modern therapies depend on platelet (PLT) transfusion support. PLTs have a 4- to 7-day shelf life and are frequently in short supply. In order to optimize the inventory PLTs are often transfused to adults without regard for ABO compatibility. Hemolytic reactions are infrequent despite the presence of ‘high titer' anti-A and anti-B antibodies in some of the units. Despite the low risk for hemolysis, some centers provide only ABO identical PLTs to their recipients; this practice might have other beneficial outcomes that remain to be proven. Strategies to mitigate the risk of hemolysis and the clinical and laboratory outcomes following ABO-matched and mismatched transfusions will be discussed. Although the PLTs themselves do not carry the D antigen, a small number of RBCs are also transfused with every PLT dose. The quantity of RBCs varies by the type of PLT preparation, and even a small quantity of D+ RBCs can alloimmunize a susceptible D- host. Thus PLT units are labeled as D+/-, and most transfusion services try to prevent the transfusion of D+ PLTs to D- females of childbearing age. A similar policy for patients with hematological diseases is controversial, and the elements and mechanisms of anti-D alloimmunization will be discussed.

show abstract

“…Platelet transfusions are typically given when thrombocytopenia is severe or individuals have ongoing serious bleeding, but may also be given on a prophylactic basis to individuals who have a significant bleeding risk based on clinical presentation and platelet counts. [1][2][3] The clinical indications for platelet transfusions, while based on medical evidence, can therefore be somewhat subjective when given on a prophylactic basis. Platelet transfusions are complicated by the unique storage conditions under which platelets must be kept, the need to keep platelets from activating during storage, and the diverse functions of platelets in health and disease.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Mediators in Platelet Transfusion Reactions

Morrell

2011

Hematology

View full text Add to dashboard Cite

Our appreciation of the roles that platelets play in vascular biology is constantly expanding. One of the major roles of platelets is in initiating and accelerating immune responses. Platelet transfusion may be associated with adverse inflammatory outcomes manifested as fever, discomfort, tachycardia, and respiratory issues. This may in part be due to immune mediators either expressed by activated platelets or released into the platelet media during platelet storage. This review will highlight some more recent knowledge gained regarding the platelet storage lesion and potential mediators of platelet transfusion reactions.

show abstract

Platelet transfusion and survival in adults with acute leukemia

Cited by 40 publications

References 6 publications

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia

Platelet Transfusion - the Art and Science of Compromise

Immunomodulatory Mediators in Platelet Transfusion Reactions

Contact Info

Product

Resources

About